More than 7 million Americans are living with Alzheimer’s disease. Earlier detection and diagnosis of Alzheimer’s would allow people to access treatments when they would be most effective and implement modifiable risk reduction strategies. As a former caregiver, I understand firsthand the importance of early detection and diagnosis. The bipartisan ASAP Act creates a pathway for Medicare coverage of FDA-approved dementia blood biomarker screening tests. The ASAP Act would also allow coverage for future test methods approved and cleared by the FDA, helping to ensure beneficiaries do not face unnecessary delays or barriers to detection and treatment. This is vital for families, especially those in rural communities.

The ASAP act represents a transformative moment for Alzheimer’s research. It is time for its passage. Please join me and the Alzheimer’s Association in encouraging Congressman John Joyce to support the bipartisan Alzheimer’s Screening and Prevention (ASAP) Act.

Sally Van Why

Bedford